1. Home
  2. Companies
  3. 15th Rock Ventures
1R

15th Rock Ventures

About

How many of us will enjoy a healthy lifespan of over 100 years old in the coming era of longevity? Why must people with disabilities have life limitations?

Human Augmentation has great potential to extend our health and lifespan to overcome limitations caused by ageing and disabilities, in order to create the world where everyone can lead a fulfilling life.

Similar companies

AH

Apollo Health Ventures

Apollo Health Ventures is a transatlantic early stage Venture Capital firm actively co-founding and investing in transformative healthcare companies targeting age-related diseases and aging itself. Biotechnology is at an inflection point and will be a primary driver of change and creator of economic value. By investing and thus enabling transformative healthcare companies in their scientific breakthroughs, we will impact human health within the next 10 years.

1 job
FL

FORM Life Ventures

We invest to‍ keep people healthy. We invest in companies to drive the shift from traditional sickcare to modern healthcare. People are not destined to become sick as they age. We believe humans can live longer and make the best of all their years. That's why we invest in companies that keep people and our environment healthy. Today, 1 out of 2 people in the world live with a chronic disease. This tragic reality is also the source of more than 80% of all healthcare costs globally. We believe the world can do better. It’s time to break the order of things. We refuse to wait until people get sick to only then be treated. We want to help people maintain and nourish their most precious resources - physical and psychological health. We’re at the front lines of this transformation by investing in pioneering early-stage companies in the US and Europe. We want to build a healthcare system that cares when it matters most. We want people to savor the joyful simplicity of optimal functioning.

WV

Windmill Ventures

We invest in exceptional founders and empower them with our expertise and time in exchange for equity, building impactful digital experiences that leave a mark on the world. Partnering with you From ideation to launch, we work with you step-by-step to build an innovative business model, develop viable prototypes, and rigorously test your product until it achieves market fit. Our venture strategy, ideation and validation, MVP launch, continuous delivery, and venture growth services are designed to free up your valuable time and accelerate your growth. Investing more than funds Unlock the potential growth of mid-stage startups with a proven core business model, focusing on the Wealthtech & Healthtech. We invest more than funds - our expertise supports you in every step of your digital product journey. Our goal is your successUnderstand: Together, we developer an innovative business model, contact potential industry partners, and implement an initial proof. Explore: We explore viable concepts and prototypes and develop user-centered products that deliver the "wow" factor. Validate: We rigorously test products with real customers and refine, refine, and refine again until we find the market fit. Launch: Engagement soars as we implement a future-proofed digital experience that your clients love. Our offer Partnering with entrepreneurs and co-founders, we support them as they scale to exit, giving them access to our global networks and services they need to grow. Venture strategy: From your idea to business model to value proposition, we work to find the right product market fit and validate these models and hypotheses with real customers. Venture ideation & validation: We build visual concepts and prototypes from your ideas, test them with real customers, and validate them with real feedback. MVP launch: We identify and define high-value, "wowable" products based on customer validation and feedback, creating a roadmap of clear increments to help the delivery plan. Continuous delivery: We work with founders and teams to successfully execute a continuous delivery and deployment program. Venture growth: We support your growth by working with you to find the right partners and opportunities.

TR

Third Rock Ventures

When we founded the firm in 2007, our imaginations were on fire with the possibility of translating scientific discoveries to breakthrough medicines. Could we finally find cures for cancer? Would we be able to diagnose diseases before they even appear? How far could we go in restoring hope and quality of life to patients with incurable conditions? We dared to believe that nothing was impossible. To achieve what hadn’t been done before, we created a process that hadn’t been done before. By starting with big ideas and fostering collaboration among brilliant people with expertise in science, medicine, business and strategy, we set out to do more than fund startups – we aim to build sustainable, innovative companies that can transform the lives of patients. Discover Our Discovery effort is a collaborative and iterative process. We look for emerging fields of science and medicine where the time is right for us to bring transformative change to areas of unmet medical need. Working with leading scientific founders and expert advisors, we then develop a clear vision and strategy for a company with the patient front and center. With 12 years and over 50 companies worth of experience, we have created an industry-leading and differentiated approach to bring breakthrough science to patients. Launch Once a company concept has been refined and optimized through our Discovery process, we Launch the company with the necessary financial, technical and human resources to enable it to reach milestones critical for its growth and success. We become active members of the company’s leadership team, serving in interim roles to ensure the execution of the company’s R&D strategy, and to build a world-class team that shares the company’s scientific vision. Importantly, we work to establish a dynamic and innovative culture at launch where the growing team has a unified passion and commitment to make a difference in the lives of patients. Build Next, we Build on that foundation. We transition out of our interim roles and establish experienced and motivated management teams. As board members and domain experts, we work with these teams for as long as is needed to relentlessly execute on the strategy, bringing whatever resources are required from within the firm to deliver on our commitment to patients. An important element is the work we do to cultivate future partnerships and drive value creating transactions. Our companies also have access to our Beyond Great learning community, which provides peer-to-peer networking for leaders across the portfolio as well as tools and resources focused on shared elements of building successful and sustainable companies. Transform Our companies are now bringing products to patients – Transforming their lives, and the lives of their families. Third Rock portfolio companies have now launched 16 products. It is this that we are most proud of, as it means we are delivering on our mission of creating great companies that discover and develop products that make a difference for the patients we serve. Mission & Core Values Third Rock's mission is to be the preferred partner for entrepreneurs, investors, employees and industry to build great companies that discover and develop products that make a difference for the patients we serve. Integrity: always do the right thing Attitude: nothing is impossible Patients: making a difference through breakthroughs in medicine Partners: make them raving fans Organization: great people, great culture, great accomplishments Entrepreneurs: passionately innovate, found, build, have fun

AV

augmenta ventures

augmenta ventures exists to redefine the possibilities of human potential through strategic investments in innovative technologies and inclusive solutions. Our commitment is encapsulated in our mission: "Investing in and Building the Future of Human Potential." By focusing on key sectors that impact society, we aim to unlock growth opportunities and empower individuals globally. This white paper explores our approach to addressing some of the most pressing global challenges through innovation, technology, and a carefully designed investment strategy. Through augmenta ventures, we co-invest in ventures enhancing life for people with limitations, from assistive tech to workforce automation. We partner with visionary founders and aligned co-investors to back scalable, inclusive solutions. Mobility Solutions: Tech that expands access and independence - from personal transportation to adaptive infrastructure. Future of Work: Solutions to support access to work for everybody Assistive & Care Technology: Innovations that improve life for people with disabilities, aging populations, or mental health challenges. Community & Connection: Platforms that reduce isolation, combat labor shortages, and foster social participation. Health & Wellness: Solutions that improve physical and mental well-being through prevention, care, and everyday health.

CB

Cambrian Biopharma

Cambrian Biopharma, a multi-asset longevity biotech, is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. By partnering with leading academic institutions and biotech entrepreneurs all over the world, we are advancing a diversified pipeline of novel therapeutics, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life as we age. Cambrian is a Distributed Development Company (or DisCo) which combines the advantages of a venture capital firm and a big pharmaceutical company, with the nimbleness of a biotech startup. Cambrian’s sourcing and development engine allows us to identify promising science, deploy capital and teams of drug development experts, and provide stewardship to advance new medicines. By leveraging established expertise and repeatable functional models, we achieve vast efficiencies in execution speed and resource utilization. To date, we have 14 novel therapeutics in development, and having closed a Series C financing round in October 2021 which raised $100 million, we plan to expand the number of programs. Further, we expect to initiate clinical trials for three programs in the next 18 months.